Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for NuCana PLC Sponsored ADR (NCNA : NSDQ)

• Company Description    NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company's pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. Number of Employees: 22

• Price / Volume Information    Yesterday's Closing Price: $0.04 Daily Weekly Monthly 20 Day Moving Average: 22,363,718 shares Shares Outstanding: 5.68 (millions) Market Capitalization: $0.24 (millions) Beta: 1.64 52 Week High: $10.79 52 Week Low: $0.04 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -94.40% -94.69% 12 Week -95.39% -95.01% Year To Date -96.47% -96.33%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3 Lochside Way - Edinburgh,X0 EH12 9DT GBR ph: 44-0-13-1357-1111 fax: - chris.brinzey@westwicke.com http://www.nucana.com

• General Corporate Information    Officers Hugh S. Griffith - Chief Executive Officer and Director Andrew Kay - Non-Executive Director and Chairman Adam George - Director Martin Mellish - Director Cyrille Leperlier - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 67022C205 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/24 Next Expected EPS Date: 05/15/25 Share - Related Items Shares Outstanding: 5.68 Most Recent Split Date: 4.00 (0.04:1) Beta: 1.64 Market Capitalization: $0.24 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/15/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.03 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 92.47% vs. Previous Quarter: 85.96% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/25 - - 12/31/24 - -313.26 09/30/24 - -314.47 ROA 03/31/25 - - 12/31/24 - -95.79 09/30/24 - -112.60 Current Ratio 03/31/25 - - 12/31/24 - 1.42 09/30/24 - 1.12 Quick Ratio 03/31/25 - - 12/31/24 - 1.42 09/30/24 - 1.12 Operating Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Net Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Pre-Tax Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Book Value 03/31/25 - - 12/31/24 - 1.34 09/30/24 - 2.14 Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - - 12/31/24 - 0.00 09/30/24 - 0.00 Debt-to-Capital 03/31/25 - - 12/31/24 - 0.00 09/30/24 - 0.00

Powered by Zacks Investment Research ©